CTR20262431 Palverafusp α Advanced Hepatocellular Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook

Turn a newly registered trial into a decision-ready landscape. This focused report examines CTR20262431—评估IMM2510联合IMM27M治疗晚期肝细胞癌患者的Ⅱ期临床研究—using PatSnap Clinical Trials MCP for protocol design and endpoint evidence, Drug & Asset MCP for mechanism and development context, and Company & Deal Intelligence MCP for sponsor background. Explore PatSnap MCP Servers to reproduce the workflow inside an AI research process.

MCP evidence snapshot: 20 July 2026; publication date: 20 July 2026. Trial records can change after the snapshot and should be rechecked before operational decisions.

Why CTR20262431 is a hot trial to watch

Advanced Hepatocellular Carcinoma is increasingly segmented by mechanism, biomarker, treatment setting, geography and endpoint architecture. CTR20262431 is notable because it evaluates Palverafusp α in a Phase 2 design while ？研究者基于RECIST v1.1标准评估客观缓解率（ORR），采用iRECIST标准作为补充。 serves as the main decision variable. The critical question is whether the protocol can convert its rationale into a clinically interpretable and operationally credible readout.

PatSnap Clinical Trials MCP makes protocol fields machine-readable, while the companion asset and organization servers add development-status, target and sponsor context.

Trial landscape snapshot

Design and endpoint interpretation

The phase label is only the starting point. Allocation is 非随机化, masking is 开放, and the intervention model is 单臂试验. Planned enrollment of 50 participants across China shapes statistical precision, execution risk and external validity. Interpretation should account for baseline risk, prior therapy, assessment schedule, missing-data handling and clinical relevance—not only statistical significance.

• Primary: ？研究者基于RECIST v1.1标准评估客观缓解率（ORR），采用iRECIST标准作为补充。 (全阶段)
• Secondary: 研究者基于RECIST v1.1标准评估的其他有效性终点，疾病控制率（DCR）、缓解持续时间（DoR）、无进展生存期（PFS），总生存期（OS）。采用iRECIST标准作为补充。 (全阶段)
• Secondary: AE、SAE发生情况和频率（根据NCI CTCAE 6.0）。 (全阶段)
• Secondary: 末次用药30天内发生的死亡事件的频率和死因。 (全阶段)
• Secondary: 药代动力学：IMM2510和IMM27M血药浓度。 (全阶段)

Benchmark readouts in the surrounding field

• A Phase 2, Multicenter, Clinical Study to Evaluate the Safety and Efficacy of MK-1308A (Coformulated MK-1308/MK-3475) in Combination With Lenvatinib (E7080/MK-7902) in First-line Therapy of Participants With Advanced Hepatocellular Carcinoma (Phase 2): Number of Participants With a Dose-Limiting Toxicity (DLT) in the Safety Lead-in Phase = 0 Participants
• Addition of ipilimumab to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma (PRODIGE 81-FFCD 2101-TRIPLET HCC): phase 2 results from a randomised, multicentre, open-label, phase 2–3 trial (Phase 2/3): Adverse Event: acute renal failure = 3% of patients in the atezolizumab plus bevacizumab group experienced acute renal failure ; Adverse Event: acute renal failure = 3% of patients in the atezolizumab plus bevacizumab group experienced acute renal failure
• Nilvanstomig (ZG005), an anti-PD-1/TIGIT bispecific antibody, plus bevacizumab vs. sintilimab plus bevacizumab biosimilar as first-line therapy for advanced hepatocellular carcinoma: A randomized, multi-center, phase II trial. (Phase 2): mPFS(per RECIST v1.1) = NR ; mPFS(per RECIST v1.1) = NR

These indexed results are contextual benchmarks, not direct head-to-head evidence. Population, treatment line, endpoint definitions, follow-up and analysis sets may differ. Their value is to clarify the type and magnitude of evidence already visible in the competitive landscape.

Build a living trial monitor: connect to PatSnap MCP Servers and track status changes, endpoint revisions, primary-completion dates and newly indexed results without manually reconciling separate databases.

Asset and sponsor context

Drug & Asset context: Palverafusp α (Phase 2; PDL1 x VEGF); Tazlestobart (Phase 2; CTLA4)

Company & Deal Intelligence context: ImmuneOnco Biopharmaceuticals (Shanghai), Inc. — China — http://cn.immuneonco.com

The sponsor profile matters because scientific rationale alone does not determine development value. Manufacturing readiness, portfolio fit, geographic reach, partnering capacity and the ability to fund confirmatory development can decide whether a positive signal becomes a competitive asset.

White space around this program

• Sharper patient selection: prospective biomarker or phenotype definitions that identify who is most likely to benefit.
• Clinically interpretable endpoints: outcomes connecting activity with function, symptoms, survival or treatment burden.
• Sequencing evidence: comparative data after the most relevant contemporary standard of care.
• Broader external validity: evidence across additional geographies, demographic groups and real-world settings.
• Operational differentiation: a development path that closes the readout gap without sacrificing safety or durability.

What to monitor next

Monitor recruitment, enrollment changes, protocol amendments, endpoint hierarchy, primary-completion timing, first result indexing, asset ownership and sponsor partnerships. A change in endpoint, population or ownership can alter probability of success before a headline data release.

Bottom line

CTR20262431 is a focused lens on Advanced Hepatocellular Carcinoma development. Its value will be determined by whether Palverafusp α can convert the current design into evidence that is clinically meaningful, operationally credible and differentiated from indexed benchmark readouts.

Ready to reproduce this analysis? Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable building blocks for trial monitoring and SEO-ready clinical reports.